FAS -670A>G promoter polymorphism is associated with soluble Fas levels in primary Sjögren's syndrome

Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of exocrine glands. Soluble Fas receptor (sFas) has been suggested as a Fas-mediated apoptosis blocker that could impair clonal deletion in infiltrated autoreactive cells. The FAS...

Full description

Saved in:
Bibliographic Details
Published in:Genetics and molecular research 2014-07, Vol.13 (3), p.4831-4838
Main Authors: Treviño-Talavera, B A, Palafox-Sánchez, C A, Muñoz-Valle, J F, Orozco-Barocio, G, Navarro-Hernández, R E, Vázquez-Del Mercado, M, García de la Torre, I, Oregon-Romero, E
Format: Article
Language:English
Subjects:
Adult
Alleles
Case-Control Studies
fas Receptor - blood
fas Receptor - genetics
Female
Gene Expression
Gene Frequency
Genotype
Heterozygote
Humans
Male
Middle Aged
Models, Genetic
Polymorphism, Genetic
Promoter Regions, Genetic
Sjogren's Syndrome - blood
Sjogren's Syndrome - genetics
Sjogren's Syndrome - pathology
Solubility
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disease characterized by lymphocytic infiltration of exocrine glands. Soluble Fas receptor (sFas) has been suggested as a Fas-mediated apoptosis blocker that could impair clonal deletion in infiltrated autoreactive cells. The FAS -670A>G promoter polymorphism has been studied in pSS. However, a relationship between FAS -670A>G promoter polymorphism and sFas levels in pSS had not been found. We examined this relationship in 77 Mexican pSS patients and 84 healthy subjects were included. Genotypes were identified by PCR-RFLP, and Fas soluble levels were quantified by ELISA. No significant differences between allele and genotype frequencies were found between these two groups. The sFas levels in the serum of pSS patients were significantly higher than in controls (9961 vs 8840 pg/mL, respectively). In addition, AA genotype carriers had significantly higher levels of sFas than GG carriers (pSS: 10,763 and 9422 pg/mL; controls: 9712 and 8305 pg/mL, respectively). An additive model analysis between genotypes (AG+GG vs AA) in both groups, demonstrated a significant association between carriers of the A allele and high sFas levels. In conclusion, carrying the double dose of A allele of FAS -670A>G polymorphism is associated with high levels of sFas in pSS, but it is not a susceptibility marker for pSS.
ISSN:1676-5680
1676-5680
DOI:10.4238/2014.July.2.12